IDEAYA Biosciences Inc., in collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate $(ADC)$. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.